Literature DB >> 23081932

Sample size determination for clinical trials with co-primary outcomes: exponential event times.

Toshimitsu Hamasaki1, Tomoyuki Sugimoto, Scott Evans, Takashi Sozu.   

Abstract

Clinical trials with event-time outcomes as co-primary contrasts are common in many areas such as infectious disease, oncology, and cardiovascular disease. We discuss methods for calculating the sample size for randomized superiority clinical trials with two correlated time-to-event outcomes as co-primary contrasts when the time-to-event outcomes are exponentially distributed. The approach is simple and easily applied in practice.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 23081932      PMCID: PMC3770150          DOI: 10.1002/pst.1545

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  12 in total

1.  Estimating significance level and power comparisons for testing multiple endpoints in clinical trials.

Authors:  J Gong; J C Pinheiro; D L DeMets
Journal:  Control Clin Trials       Date:  2000-08

2.  Sample size determination in clinical trials with multiple co-primary binary endpoints.

Authors:  Takashi Sozu; Tomoyuki Sugimoto; Toshimitsu Hamasaki
Journal:  Stat Med       Date:  2010-09-20       Impact factor: 2.373

3.  Challenge of multiple co-primary endpoints: a new approach.

Authors:  Christy Chuang-Stein; Paul Stryszak; Alex Dmitrienko; Walter Offen
Journal:  Stat Med       Date:  2007-03-15       Impact factor: 2.373

4.  Power and sample size when multiple endpoints are considered.

Authors:  Stephen Senn; Frank Bretz
Journal:  Pharm Stat       Date:  2007 Jul-Sep       Impact factor: 1.894

5.  Sample size calculation for the weighted rank statistics with paired survival data.

Authors:  Sin-Ho Jung
Journal:  Stat Med       Date:  2008-07-30       Impact factor: 2.373

6.  A statistical model for the dependence between progression-free survival and overall survival.

Authors:  Frank Fleischer; Birgit Gaschler-Markefski; Erich Bluhmki
Journal:  Stat Med       Date:  2009-09-20       Impact factor: 2.373

7.  Sample size determination in superiority clinical trials with multiple co-primary correlated endpoints.

Authors:  Takashi Sozu; Tomoyuki Sugimoto; Toshimitsu Hamasaki
Journal:  J Biopharm Stat       Date:  2011-07       Impact factor: 1.051

8.  Sample size determination in clinical trials with multiple co-primary endpoints including mixed continuous and binary variables.

Authors:  Takashi Sozu; Tomoyuki Sugimoto; Toshimitsu Hamasaki
Journal:  Biom J       Date:  2012-07-25       Impact factor: 2.207

9.  Another view on the analysis of cardiovascular morbidity/mortality trials.

Authors:  Gerd K Rosenkranz
Journal:  Pharm Stat       Date:  2010-04-22       Impact factor: 1.894

10.  Introduction to sample size determination and power analysis for clinical trials.

Authors:  J M Lachin
Journal:  Control Clin Trials       Date:  1981-06
View more
  12 in total

Review 1.  Design, data monitoring, and analysis of clinical trials with co-primary endpoints: A review.

Authors:  Toshimitsu Hamasaki; Scott R Evans; Koko Asakura
Journal:  J Biopharm Stat       Date:  2017-10-30       Impact factor: 1.051

2.  Group-Sequential Strategies in Clinical Trials with Multiple Co-Primary Outcomes.

Authors:  Toshimitsu Hamasaki; Koko Asakura; Scott R Evans; Tomoyuki Sugimoto; Takashi Sozu
Journal:  Stat Biopharm Res       Date:  2015       Impact factor: 1.452

3.  A logrank test-based method for sizing clinical trials with two co-primary time-to-event endpoints.

Authors:  Tomoyuki Sugimoto; Takashi Sozu; Toshimitsu Hamasaki; Scott R Evans
Journal:  Biostatistics       Date:  2013-01-10       Impact factor: 5.899

4.  Sample size determination in group-sequential clinical trials with two co-primary endpoints.

Authors:  Koko Asakura; Toshimitsu Hamasaki; Tomoyuki Sugimoto; Kenichi Hayashi; Scott R Evans; Takashi Sozu
Journal:  Stat Med       Date:  2014-03-27       Impact factor: 2.373

5.  Group cognitive rehabilitation to reduce the psychological impact of multiple sclerosis on quality of life: the CRAMMS RCT.

Authors:  Nadina B Lincoln; Lucy E Bradshaw; Cris S Constantinescu; Florence Day; Avril Er Drummond; Deborah Fitzsimmons; Shaun Harris; Alan A Montgomery; Roshan das Nair
Journal:  Health Technol Assess       Date:  2020-01       Impact factor: 4.014

6.  Group-sequential three-arm noninferiority clinical trial designs.

Authors:  Toshimitsu Ochiai; Toshimitsu Hamasaki; Scott R Evans; Koko Asakura; Yuko Ohno
Journal:  J Biopharm Stat       Date:  2016-02-18       Impact factor: 1.051

7.  Sizing clinical trials when comparing bivariate time-to-event outcomes.

Authors:  Tomoyuki Sugimoto; Toshimitsu Hamasaki; Scott R Evans; Takashi Sozu
Journal:  Stat Med       Date:  2017-01-24       Impact factor: 2.373

8.  Sample Size Considerations in Clinical Trials when Comparing Two Interventions using Multiple Co-Primary Binary Relative Risk Contrasts.

Authors:  Yuki Ando; Toshimitsu Hamasaki; Scott R Evans; Koko Asakura; Tomoyuki Sugimoto; Takashi Sozu; Yuko Ohno
Journal:  Stat Biopharm Res       Date:  2015-06-24       Impact factor: 1.452

9.  Interim evaluation of efficacy or futility in group-sequential trials with multiple co-primary endpoints.

Authors:  Koko Asakura; Toshimitsu Hamasaki; Scott R Evans
Journal:  Biom J       Date:  2016-10-19       Impact factor: 2.207

10.  Interim Monitoring for Futility in Clinical Trials with Two Co-primary Endpoints Using Prediction.

Authors:  Koko Asakura; Scott R Evans; Toshimitsu Hamasaki
Journal:  Stat Biopharm Res       Date:  2019-11-04       Impact factor: 1.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.